{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:11:38Z","timestamp":1761883898598,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.reumae.2020.07.010","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:16:01Z","timestamp":1617754561000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and\/or spondyloarthritis and initiating treatment with secukinumab"],"prefix":"10.1016","volume":"18","author":[{"given":"Juan Jos\u00e9 Lerma","family":"Garrido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Gracia","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio P\u00e9rez","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia Rueda","family":"Cid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Molina","family":"Almela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores Pastor","family":"Cubillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Campos","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel Balaguer","family":"Trull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Calvo","family":"Catal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2020.07.010_bib0005","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.reumae.2020.07.010_bib0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/ard.2003.006296","article-title":"Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis","volume":"63","author":"McKenna","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.07.010_bib0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2020.07.010_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00393-008-0361-y","article-title":"Ankylosing spondylitis: target treatment criteria","volume":"68","author":"Braun","year":"2009","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.reumae.2020.07.010_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2020.07.010_bib0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in psoriatic arthritis: a randomized, double-blind, placebo-controlled, phase 3 trial (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.07.010_bib0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.07.010_bib0045","article-title":"UvA-DARE (Digital Academic Repository) Spondyloarthritis: from disease phenotypes to novel treatments Paramarta","author":"Paramarta","year":"2017","journal-title":"Jacky"},{"key":"10.1016\/j.reumae.2020.07.010_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.reumae.2020.07.010_bib0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.2006.065763","article-title":"Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis","volume":"66","author":"Chandran","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0212-6567(01)70406-4","article-title":"EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care","volume":"28","author":"Herdman","year":"2001","journal-title":"Aten Primaria"},{"key":"10.1016\/j.reumae.2020.07.010_bib0065","first-page":"550","article-title":"La evaluaci\u00f3n de la calidad de vida en el contexto del ensayo cl\u00ednico","volume":"110","author":"Badia","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.reumae.2020.07.010_bib0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.reumae.2020.07.010_bib0075","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3122\/jabfm.2013.06.130064","article-title":"Validation of the insomnia severity index in primary care","volume":"26","author":"Gagnon","year":"2013","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.reumae.2020.07.010_bib0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.reumae.2020.07.010_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0055912","article-title":"Validity and reliability of the dutch adaptation of the psoriatic arthritis quality of life (PsAQoL) questionnaire","volume":"8","author":"Wink","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2020.07.010_bib0090","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.07.010_bib0095","first-page":"2521","article-title":"Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: Methotrexate as the anchor drug in 90% and new DMARD in 30% of patients","volume":"29","author":"Sokka","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2020.07.010_bib0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0105","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/imt-2016-0128","article-title":"Secukinumab in the treatment of psoriasis: an update","volume":"9","author":"Reszke","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.reumae.2020.07.010_bib0120","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.reumae.2020.07.010_bib0130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.07.010_bib0135","first-page":"1","article-title":"Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature","volume":"22","author":"Abrouk","year":"2017","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.reumae.2020.07.010_bib0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: Results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.07.010_bib0145","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.reumae.2020.07.010_bib0150","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:00:50Z","timestamp":1761879650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574321000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2173574321000721"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2020.07.010","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and\/or spondyloarthritis and initiating treatment with secukinumab","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2020.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2020.07.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}